共 89 条
[1]
Go AS(2004)Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296-1305
[2]
Chertow GM(2005)Serum phosphate levels and mortality risk among people with chronic kidney disease J Am Soc Nephrol 16 520-528
[3]
Fan D(2009)Association of serum phosphate with vascular and valvular calcification in moderate CKD J Am Soc Nephrol 20 381-387
[4]
McCulloch CE(2011)A Japanese approach for CKD-MBD Kidney Int Suppl 2013 451-456
[5]
Hsu CY(2014)Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis J Ren Nutr 24 261-267
[6]
Kestenbaum B(2014)JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis Nephron Clin Pract 128 135-140
[7]
Sampson JN(2014)Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD Clin J Am Soc Nephrol 9 543-552
[8]
Rudser KD(2021)Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study Int J Hematol 114 8-17
[9]
Patterson DJ(2019)Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study Sci Rep 9 8877-1858
[10]
Seliger SL(2017)Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia J Am Soc Nephrol 6 1851-1297